Fig 1: Nuclear Lamin B1 levels are restored in memory B cells and low LMNB1 expression level is an adverse prognostic factor in CLL. (a) Fresh frozen normal human lymph nodes were fixed in −20 °C methanol and then stained with PNA (blue), Lamin B1 (green) and anti-CD27 antibodies (red). (b) A zoomed in the area of (A, square) representing differential Lamin B1 expression in CD27+ vs CD27- cell. (c) High-throughput comparison of Lamin B1 levels in CD27+ and CD27- GC cells. Lymph nodes from three patients were assessed and in total 50 randomly selected CD27+, and 50 randomly selected CD27- GC cells were analysed using MetaMorph software. (d, e) showing Kaplan–Meier estimates of progression-free (PFS) (d) and overall (OS) (e) of CLL patients enrolled on the CLL8-trial as a factor of LMNB1 expression, dichotomised by the median (>6.51, N=168 and ⩽6.51, N=169. (f) Univariate Cox regression analysis comparing low (⩽6.51, N=169) and high (>6.51, N=168) LMNB1 expressing CLL patients as a factor of the treatment regime (FC or FCR) applied. *P<0.05, **P<0.01, ***P<0.001.